【24h】

Wandering Ozurdex ? implant

机译:游走的Ozurdex?注入

获取原文
           

摘要

To report the behavior of intravitreal Ozurdex? implant in eyes with post-lensectomy–vitrectomy (PLV) aphakia. Retrospective chart review of three eyes with PLV aphakia (three patients with uveitis) who received intravitreal injection of Ozurdex? for cystoid macular edema (one eye), persistent inflammation (one eye), and ocular hypotony (one eye). Final outcome was assessed in terms of effectiveness, stability, and tolerance of the implant. Following the implant, an initial improvement was seen in all the three eyes. However, the implant migrated into the anterior chamber (AC) at 1?week in two eyes and at 5?weeks in one eye, and wandered between the AC and vitreous cavity with changing postures of the patient. Two eyes developed corneal edema, of which one eye underwent implant removal from the AC. Ozurdex? implant should be contraindicated in eyes with PLV aphakia to avoid its deleterious effect on the corneal endothelium.
机译:要报告玻璃体内Ozurdex的行为?晶状体切除术-玻璃体切除术(PLV)无晶状体植入眼内。玻璃体腔内注射Ozurdex的3眼PLV无晶状体无晶体眼(3例葡萄膜炎)的回顾性图表回顾?用于黄斑囊样水肿(一只眼),持续性炎症(一只眼)和眼肌张力低下(一只眼)。根据植入物的有效性,稳定性和耐受性评估最终结果。植入后,三只眼睛均得到了初步改善。但是,植入物在两只眼中每隔1周和一只眼中每隔5周移入前房(AC),并随着患者姿势的变化而在AC和玻璃体腔之间游荡。两只眼睛发展为角膜水肿,其中一只眼睛接受了AC种植体切除。 Ozurdex? PLV无晶状体眼应禁忌植入物,以免其对角膜内皮的有害作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号